Artiva Biotherapeutics ARTV
NASDAQ ARTV
$6.30 -0.19 (-3.00%)
As of: Oct 22, 2026 · 1:16 PM EDT

Artiva Biotherapeutics (ARTV) Receivables (2023 - 2026)

Updated

Artiva Biotherapeutics (ARTV) reported Receivables of $141,000 for Q2 2026, up 370.0% from $30,000 a year earlier.

Analysis

Artiva Biotherapeutics (ARTV) Receivables (2023 - 2026) Analysis & Trends

At the end of FY2025, Artiva Biotherapeutics posted Receivables of $67,000, down 54.1% from FY2024.

  • By year, Receivables came in at $146,000 in FY2024 (-91.7%) and $1.76 million in FY2023.
  • The Q2 2026 figure ranks as the highest quarterly Receivables since Q1 2025.
  • Year over year, Receivables gained in 1 of the last five quarters, with growth averaging 7.5%.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,166.97 Bn 1,135.56 Bn 19.71 Bn 23.48 Bn
2 Johnson & Johnson 644.38 Bn 564.24 Bn 17.30 Bn 18.99 Bn
3 AbbVie 501.54 Bn 474.65 Bn 12.70 Bn 13.82 Bn
4 Merck 359.36 Bn 313.74 Bn 12.21 Bn 12.56 Bn
5 Novartis Ag 302.13 Bn 266.12 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 267.59 Bn 241.28 Bn 12.86 Bn 15.68 Bn
7 Amgen 241.49 Bn 196.89 Bn 7.24 Bn 10.23 Bn
8 Gilead Sciences 192.85 Bn 167.05 Bn 6.22 Bn 5.06 Bn
9 Pfizer 171.77 Bn 118.41 Bn 10.94 Bn 12.49 Bn
10 Artiva Biotherapeutics 248.30 Mn -101.10 Mn - 141,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 141,000.00
Dec 31, 2025 67,000.00
Sep 30, 2025 79,000.00
Jun 30, 2025 30,000.00
Mar 31, 2025 234,000.00
Dec 31, 2024 146,000.00
Sep 30, 2024 701,000.00
Jun 30, 2024 1.46 Mn
Dec 31, 2023 1.76 Mn
API Access

Artiva Biotherapeutics Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=ARTV&period=max&api_key=YOUR_API_KEY